Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Lifshitz Law PLLC Announces Investigations of Orthofix Medical Inc. (NASDAQ:OFIX), DexCom, Inc. (NASDAQ:DXCM), Methode Electronics, Inc. (NYSE:MEI), and Verve Therapeutics, Inc. (NASDAQ:VERV).

DXCM, MEI, OFIX, VERV

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Lifshitz Law Firm

Orthofix Medical Inc. (NASDAQ:OFIX)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information about the Company's management team. On September 12, 2023, Orthofix announced it had terminated three executives in the Company for cause, following an investigation conducted by independent counsel. The Company stated that "the Board determined that each of these executives engaged in repeated inappropriate and offensive conduct that violated multiple code of conduct requirements and was inconsistent with the Company's values and culture." Following this news, the price of the Company's stock dropped.

If you are an OFIX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

DexCom, Inc. (NASDAQ:DXCM)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose material information concerning DexCom's expected revenue for the fiscal year 2024. The Company's statements included, among other things, confidence in DexCom's ability to capitalize on its growth potential to reach the projected record number of new patients and simultaneously outpace the prior fiscal year's gross margins, while scaling customer conversion to the new G7 platform. However, the Company allegedly failed to disclose the true state of DexCom's salesforce; notably, that it was not truly equipped to execute on the Company's perceived growth potential, and that as a result of their purchases of DexCom's common stock investors suffered economic loss.

If you are a DXCM investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail atinfo@lifshitzlaw.com.

Methode Electronics, Inc. (NYSE:MEI)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made materially false and/or misleading statements and/or failed to disclose material information. Specifically, the Company allegedly made false and/or misleading statements and/or failed to disclose that: (i) Methode Electronics had lost highly skilled and experienced employees during the COVID-19 pandemic necessary to successfully complete Methode Electronics' transition from its historic low mix, high volume production model to a high mix, low production model at its Monterrey facility; (ii) Methode Electronics' attempts to replace its General Motors center console production with more diversified, specialized products for a wider array of vehicle manufacturers and OEMs, in particular in the electric vehicle ("EV") space, had been plagued by production planning deficiencies, inventory shortages, vendor and supplier problems, and, ultimately, botched execution of Methode Electronics' strategic plans; (iii) Methode Electronics' manufacturing systems at its critical Monterrey facility suffered from a variety of logistical defects, such as improper system coding, shipping errors, erroneous delivery times, deficient quality control systems, and failures to timely and efficiently procure necessary raw materials; (iv) Methode Electronics had fallen substantially behind on the launch of new EV programs out of its Monterrey facility, preventing Methode Electronics from timely receiving revenue from new EV program awards; and (v) as a result, Methode Electronics was not on track to achieve the 2023 diluted earnings-per-share guidance or the 3-year 6% organic sales compound annual growth rate represented to investors and such estimates lacked a reasonable factual basis.

If you are an MEI investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

Verve Therapeutics, Inc. (NASDAQ:VERV)

Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made misrepresentations and omissions related to the Company's business, operations and prospects, which were known to the Company or recklessly disregarded by them. Specifically, the Company allegedly made false and/or misleading statements and/or failed to disclose that: (i) the Company did not fully disclose the circumstances under which the Heart-1 trial would be halted; (ii) the Company overstated the potential benefits of its proprietary LNP delivery system (iii) as a result, the Company's statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

If you are a VERV investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.

ATTORNEY ADVERTISING.© 2025 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact:

Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: jlifshitz@lifshitzlaw.com

SOURCE: Lifshitz Law Firm



View the original press release on accesswire.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today